摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

dibenzyl 2-(3-benzo[b]furyl)-6,7-methylenedioxy-quinolin-4-ylphosphate | 1355235-76-5

中文名称
——
中文别名
——
英文名称
dibenzyl 2-(3-benzo[b]furyl)-6,7-methylenedioxy-quinolin-4-ylphosphate
英文别名
dibenzyl 2-(3-benzo[b]furyl)-6,7-methylenedioxyquinolin-4-yl phosphate;[6-(1-benzofuran-3-yl)-[1,3]dioxolo[4,5-g]quinolin-8-yl] dibenzyl phosphate
dibenzyl 2-(3-benzo[b]furyl)-6,7-methylenedioxy-quinolin-4-ylphosphate化学式
CAS
1355235-76-5
化学式
C32H24NO7P
mdl
——
分子量
565.519
InChiKey
DQUMRZRJSSIVLZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.5
  • 重原子数:
    41
  • 可旋转键数:
    9
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    89.2
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    dibenzyl 2-(3-benzo[b]furyl)-6,7-methylenedioxy-quinolin-4-ylphosphate 碳酸氢钠丙酮 作用下, 以 甲醇 为溶剂, 反应 0.25h, 以to give 158的产率得到2-(3-benzo[b]furyl)-.6,7-methylenedioxy-quinolin-4-yldihydrogenphosphate
    参考文献:
    名称:
    SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES
    摘要:
    以下公式I的化合物被披露,或其药学上可接受的盐、前药、溶剂化物或代谢物,其中: R为氢、P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、P(═O)(OM)2、P═O(O2M)、S(═O)(OH)2、S(═O)(O(C1-C18)烷基(C6-C20)芳基)2、S(═O)(OH)(OM)、S(═O)(OM)2; M为单价或二价金属离子或烷基铵离子; W为(C6-C20)芳基、(C6-C20)杂芳基、(C1-C18)烷基(C6-C20)芳基、(C1-C18)烷基(C6-C20)杂芳基、羟基(C6-C20)芳基、羟基(C6-C20)杂芳基、(C1-C18)烷氧基(C6-C20)芳基、(C1-C18)烷氧基(C6-C20)杂芳基、(C1-C18)烷二氧基(C6-C20)芳基、(C1-C18)烷二氧基(C6-C20)杂芳基、卤代(C6-C20)芳基、卤代(C6-C20)杂芳基、(C1-C18)烷基氨基(C6-C20)芳基、(C1-C18)烷基氨基(C6-C20)杂芳基、(C1-C18)环烷基氨基(C6-C20)芳基或(C1-C18)环烷基氨基(C6-C20)杂芳基及其OR8取代基; R5为(C1-C18)烷氧基、氢、羟基、O-(C1-C18)烷基(C6-C20)芳基、卤代或OR8,或者R5和R6为(C1-C18)二氧基,前提是R7为氢; R6为羟基、O-(C1-C18)烷基(C6-C20)芳基、卤代或ORR、(C1-C18)烷氧基、(C1-C18)烷基氨基或(C1-C18)环烷基氨基,或者R6和R7为(C1-C18)二氧基,前提是R5为氢; R7为氢、卤代或OR8、羟基或O-(C1-C18)烷基(C6-C20)芳基; R8为P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)或P(═O)(OM)2、P═O(O2M)。
    公开号:
    US20120015908A1
  • 作为产物:
    描述:
    苯并[B]呋喃-3-甲酰氯potassium tert-butylate 、 sodium hydride 、 三乙胺 作用下, 以 四氢呋喃甲苯 、 mineral oil 、 叔丁醇 为溶剂, 反应 28.0h, 生成 dibenzyl 2-(3-benzo[b]furyl)-6,7-methylenedioxy-quinolin-4-ylphosphate
    参考文献:
    名称:
    SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES
    摘要:
    根据以下公式披露了一种化合物:或其药学上可接受的盐、前药、溶剂合物或代谢物,其中R为氢、P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、P(═O)(OM)2、P═O(O2M)、S(═O)(OH)2、S(═O)(O(C1-C18)烷基(C6-C20)芳基)2、S(═O)(OH)(OM)、S(═O)(OM)2;M为一价或二价金属离子,或烷基铵离子;W为(C6-C20)芳基、(C6-C20)杂芳基、(C1-C18)烷基(C6-C20)芳基、(C1-C18)烷基(C6-C20)杂芳基、羟基(C6-C20)芳基、羟基(C6-C20)杂芳基、(C1-C18)烷氧基(C6-C20)芳基、(C1-C18)烷氧基(C6-C20)杂芳基、(C1-C18)烷二氧基(C6-C20)芳基、(C1-C18)烷二氧基(C6-C20)杂芳基、卤代(C6-C20)芳基、卤代(C6-C20)杂芳基、(C1-C18)烷基氨基(C6-C20)芳基、(C1-C18)烷基氨基(C6-C20)杂芳基、(C1-C18)环烷基氨基(C6-C20)芳基,或(C1-C18)环烷基氨基(C6-C20)杂芳基,以及它们的OR8取代基;R5为(C1-C18)烷氧基、氢、羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或OR8,或R5和R6为(C1-C18)二氧基,前提是R7为氢;R6为羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或ORR、(C1-C18)烷氧基、(C1-C18)烷基氨基,或(C1-C18)环烷基氨基,或R6和R7为(C1-C18)二氧基,前提是R5为氢;R7为氢、卤素或OR8、羟基,或O—(C1-C18)烷基(C6-C20)芳基;R8为P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、或P(═O)(OM)2、P═O(O2M)。
    公开号:
    US20120015908A1
点击查看最新优质反应信息

文献信息

  • NOVEL USE OF ARYL-QUINOLIN DERIVATIVES AS INHIBITORS OF VASCULOGENIC MIMICRY
    申请人:TaiRx Inc.
    公开号:US20160354361A1
    公开(公告)日:2016-12-08
    Aryl-quinolin derivatives for use in inhibiting vasculogenic mimicry, treating diseases characterized by abnormal vascular morphology or function and/or by the presence of vasculogenic mimicry in a subject in need thereof are disclosed. In one embodiment of the invention, the compounds are for use in treating metastatic tumor, hyperproliferative, or angiogenic diseases, in another embodiment of the invention, the compound for use may combine an additional therapeutic agent such as anti-cancer agents, anti-inflammatory agents, anti-proliferative agents, anti-hormonal agents, or any combination thereof for use.
  • US8524740B2
    申请人:——
    公开号:US8524740B2
    公开(公告)日:2013-09-03
  • SYNTHESIS AND ANTICANCER ACTIVITY OF ARYL AND HETEROARYL-QUINOLIN DERIVATIVES
    申请人:Kuo Sheng-Chu
    公开号:US20120015908A1
    公开(公告)日:2012-01-19
    A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH) 2 , P(═O)(O(C 1 -C 18 )alkylene(C 6 -C 20 )aryl) 2 , P(═O)(OH)(OM), P(═O)(OM) 2 , P═O(O 2 M), S(═O)(OH) 2 , S(═O)(O(C 1 -C 18 )alkylene(C 6 -C 20 )aryl) 2 , S(═O)(OH)(OM), S(═O)(OM) 2 ; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C 6 -C 20 )aryl, (C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkyl(C 6 -C 20 )aryl, (C 1 -C 18 )alkyl(C 6 -C 20 )heteroaryl, hydroxy(C 6 -C 20 )aryl, hydroxy(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkoxy(C 6 -C 20 )aryl, (C 1 -C 18 )alkoxy(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkylenedioxy(C 6 -C 20 )aryl, (C 1 -C 18 )alkylenedioxy(C 6 -C 20 )heteroaryl, halo(C 6 -C 20 )aryl, halo(C 6 -C 20 )heteroaryl, (C 1 -C 18 )alkylamino(C 6 -C 20 )aryl, (C 1 -C 18 )alkylamino(C 6 -C 20 )heteroaryl, (C 1 -C 18 )cycloalkylamino(C 6 -C 20 )aryl, or (C 1 -C 18 )cycloalkylamino(C 6 -C 20 )heteroaryl, and their OR 8 substutes; R 5 is (C 1 -C 18 alkoxy, hydrogen, hydroxyl, O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl, halo or OR 8 , or R 5 and R 6 are (C 1 -C 18 )dioxy provided that R 7 is hydrogen; R 6 is hydroxyl, O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl, halo or OR R , (C 1 -C 18 )alkoxy, (C 1 -C 18 )alkylamino, or (C 1 -C 18 )cycloalkylamino, or R 6 and R 7 are (C 1 -C 18 )dioxy provided that R 5 is hydrogen; R 7 is hydrogen, halo or OR 8 , hydroxyl, or O—(C 1 -C 18 )alkyl(C 6 -C 20 )aryl; and R 8 is P(═O)(OH) 2 , P(═O)(O(C 1 -C 18 )alkyl(C 6 -C 20 )aryl) 2 , P(═O)(OH)(OM), or P(═O)(OM) 2 , P═O(O 2 M).
    根据以下公式披露了一种化合物:或其药学上可接受的盐、前药、溶剂合物或代谢物,其中R为氢、P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、P(═O)(OM)2、P═O(O2M)、S(═O)(OH)2、S(═O)(O(C1-C18)烷基(C6-C20)芳基)2、S(═O)(OH)(OM)、S(═O)(OM)2;M为一价或二价金属离子,或烷基铵离子;W为(C6-C20)芳基、(C6-C20)杂芳基、(C1-C18)烷基(C6-C20)芳基、(C1-C18)烷基(C6-C20)杂芳基、羟基(C6-C20)芳基、羟基(C6-C20)杂芳基、(C1-C18)烷氧基(C6-C20)芳基、(C1-C18)烷氧基(C6-C20)杂芳基、(C1-C18)烷二氧基(C6-C20)芳基、(C1-C18)烷二氧基(C6-C20)杂芳基、卤代(C6-C20)芳基、卤代(C6-C20)杂芳基、(C1-C18)烷基氨基(C6-C20)芳基、(C1-C18)烷基氨基(C6-C20)杂芳基、(C1-C18)环烷基氨基(C6-C20)芳基,或(C1-C18)环烷基氨基(C6-C20)杂芳基,以及它们的OR8取代基;R5为(C1-C18)烷氧基、氢、羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或OR8,或R5和R6为(C1-C18)二氧基,前提是R7为氢;R6为羟基、O—(C1-C18)烷基(C6-C20)芳基、卤素或ORR、(C1-C18)烷氧基、(C1-C18)烷基氨基,或(C1-C18)环烷基氨基,或R6和R7为(C1-C18)二氧基,前提是R5为氢;R7为氢、卤素或OR8、羟基,或O—(C1-C18)烷基(C6-C20)芳基;R8为P(═O)(OH)2、P(═O)(O(C1-C18)烷基(C6-C20)芳基)2、P(═O)(OH)(OM)、或P(═O)(OM)2、P═O(O2M)。
  • Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives
    申请人:Kuo Sheng-Chu
    公开号:US08524740B2
    公开(公告)日:2013-09-03
    A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(═O)(OH)2, P(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, P(═O)(OH)(OM), P(═O)(OM)2, P═O(O2M), S(═O)(OH)2, S(═O)(O(C1-C18)alkylene(C6-C20)aryl)2, S(═O)(OH)(OM), S(═O)(OM)2; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C6-C20)aryl, (C6-C20)heteroaryl, (C1-C18)alkyl(C6-C20)aryl, (C1-C18)alkyl(C6-C20)heteroaryl, hydroxy(C6-C20)aryl, hydroxy(C6-C20)heteroaryl, (C1-C18)alkoxy(C6-C20)aryl, (C1-C18)alkoxy(C6-C20)heteroaryl, (C1-C18)alkylenedioxy(C6-C20)aryl, (C1-C18)alkylenedioxy(C6-C20)heteroaryl, halo(C6-C20)aryl, halo(C6-C20)heteroaryl, (C1-C18)alkylamino(C6-C20)aryl, (C1-C18)alkylamino(C6-C20)heteroaryl, (C1-C18)cycloalkylamino(C6-C20)aryl, or (C1-C18)cycloalkylamino(C6-C20)heteroaryl, and their OR8 substutes; R5 is (C1-C18alkoxy, hydrogen, hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or OR8, or R5 and R6 are (C1-C18)dioxy provided that R7 is hydrogen; R6 is hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or OR8, (C1-C18)alkoxy, (C1-C18)alkylamino, or (C1-C18)cycloalkylamino, or R6 and R7 are (C1-C18)dioxy provided that R5 is hydrogen; R7 is hydrogen, halo or OR8, hydroxyl, or O—(C1-C18)alkyl(C6-C20)aryl; and R8 is P(═O)(OH)2, P(═O)(O(C1-C18)alkyl(C6-C20)aryl)2, P(═O)(OH)(OM), or P(═O)(OM)2, P═O(O2M).
    以下公式I的化合物被披露,或其药学上可接受的盐,前药,溶剂化物或代谢物,其中: R是氢,P(═O)(OH)2,P(═O)(O(C1-C18)烷基(C6-C20)芳基)2,P(═O)(OH)(OM),P(═O)(OM)2,P═O(O2M),S(═O)(OH)2,S(═O)(O(C1-C18)烷基(C6-C20)芳基)2,S(═O)(OH)(OM),S(═O)(OM)2; M是一价或二价金属离子或烷基铵离子; W是(C6-C20)芳基,(C6-C20)杂环芳基,(C1-C18)烷基(C6-C20)芳基,(C1-C18)烷基(C6-C20)杂环芳基,羟基(C6-C20)芳基,羟基(C6-C20)杂环芳基,(C1-C18)烷氧基(C6-C20)芳基,(C1-C18)烷氧基(C6-C20)杂环芳基,(C1-C18)烷二氧基(C6-C20)芳基,(C1-C18)烷二氧基(C6-C20)杂环芳基,卤代(C6-C20)芳基,卤代(C6-C20)杂环芳基,(C1-C18)烷基氨基(C6-C20)芳基,(C1-C18)烷基氨基(C6-C20)杂环芳基,(C1-C18)环烷基氨基(C6-C20)芳基或(C1-C18)环烷基氨基(C6-C20)杂环芳基,以及它们的OR8取代基; R5是(C1-C18)烷氧基,氢,羟基,O-(C1-C18)烷基(C6-C20)芳基,卤代或OR8,或R5和R6是(C1-C18)二氧基,前提是R7是氢; R6是羟基,O-(C1-C18)烷基(C6-C20)芳基,卤代或OR8,(C1-C18)烷氧基,(C1-C18)烷基氨基或(C1-C18)环烷基氨基,或R6和R7是(C1-C18)二氧基,前提是R5是氢; R7是氢,卤代或OR8,羟基或O-(C1-C18)烷基(C6-C20)芳基; R8是P(═O)(OH)2,P(═O)(O(C1-C18)烷基(C6-C20)芳基)2,P(═O)(OH)(OM)或P(═O)(OM)2,P═O(O2M)。
查看更多